Active ingredientBrigatinibCat. No. P-B105-001CAS 1197953-54-0Family · Pharmaceutical analytical standards
Brigatinib
A tyrosine kinase inhibitor aimed mainly at ALK, for ALK-positive non-small cell lung cancer: approved in the United States in 2017 and, as first-line treatment, in 2020. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?It contains a chemical group rarely seen in medicines, a phosphine oxide, so distinctive that it even appears in the title of the scientific paper announcing its discovery.
Go to the active ingredient →Active ingredientBrigatinibCat. No. P-B105-001CAS 1197953-54-0
Isotopically labelledBrigatinib-d11Cat. No. P-B105-002
Isotopically labelledBrigatinib-d3Cat. No. P-B105-003CAS 2055306-71-1
ImpurityBrigatinib Impurity 1Cat. No. P-B105-004CAS 1197953-49-3
ImpurityBrigatinib Impurity 2Cat. No. P-B105-005CAS 761440-75-9
ImpurityBrigatinib Impurity 3Cat. No. P-B105-008CAS 1259274-28-6No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.